COVID-19 : On the threshold of the fifth year. The situation in Spain
©The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)..
Despite having emerged from pandemic status, the incidence of COVID-19 episodes has recently increased in Spain, including pediatric cases and admissions to Intensive Care Units. Several recombinant variants are circulating among us, particularly XBB arising from two Omicron BA.2 sublineages with mutations in the genes encoding the spicule proteins that could increase binding to the ACE2 receptor and be more prone to immune escape. Faced with these, 3 pharmaceutical companies have developed vaccines adapted to the XBB.1.5 sublineage that are already available for administration in our setting with risks that should not be different from those of previous mRNA vaccines and with clearly favorable benefit/risk ratios. They should be applied to patients with potential for poor COVID-19 evolution and to collectives that have a particular relationship of proximity with them. Their application should be understood not only from a perspective of individual convenience but also from that of collective responsibility. The most convenient seems to be a simultaneous immunization of COVID-19 and influenza in our environment. In the therapeutic aspect, there is little to expect right now from antisera, but the already known antiviral drugs are still available and indicated, although their efficacy will have to be reevaluated due to their impact on populations that are mostly immunized and with a better prognosis than in the past. In our opinion, it is necessary to continue to make a reasonable and timely use of masks and other non-pharmacological means of protection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 37(2024), 1 vom: 19. Feb., Seite 17-28 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodríguez-Artalejo, F J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 20.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/123.2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365006394 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365006394 | ||
| 003 | DE-627 | ||
| 005 | 20240220232208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.37201/req/123.2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM365006394 | ||
| 035 | |a (NLM)38009431 | ||
| 035 | |a (PII)rodriguez27nov2023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodríguez-Artalejo, F J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 |b On the threshold of the fifth year. The situation in Spain |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). | ||
| 520 | |a Despite having emerged from pandemic status, the incidence of COVID-19 episodes has recently increased in Spain, including pediatric cases and admissions to Intensive Care Units. Several recombinant variants are circulating among us, particularly XBB arising from two Omicron BA.2 sublineages with mutations in the genes encoding the spicule proteins that could increase binding to the ACE2 receptor and be more prone to immune escape. Faced with these, 3 pharmaceutical companies have developed vaccines adapted to the XBB.1.5 sublineage that are already available for administration in our setting with risks that should not be different from those of previous mRNA vaccines and with clearly favorable benefit/risk ratios. They should be applied to patients with potential for poor COVID-19 evolution and to collectives that have a particular relationship of proximity with them. Their application should be understood not only from a perspective of individual convenience but also from that of collective responsibility. The most convenient seems to be a simultaneous immunization of COVID-19 and influenza in our environment. In the therapeutic aspect, there is little to expect right now from antisera, but the already known antiviral drugs are still available and indicated, although their efficacy will have to be reevaluated due to their impact on populations that are mostly immunized and with a better prognosis than in the past. In our opinion, it is necessary to continue to make a reasonable and timely use of masks and other non-pharmacological means of protection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a masks | |
| 650 | 4 | |a molnupiravir | |
| 650 | 4 | |a nirmatrelvir-ritonavir | |
| 650 | 4 | |a recombinant variants | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Ruiz-Galiana, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cantón, R |e verfasserin |4 aut | |
| 700 | 1 | |a De Lucas Ramos, P |e verfasserin |4 aut | |
| 700 | 1 | |a García-Botella, A |e verfasserin |4 aut | |
| 700 | 1 | |a García-Lledó, A |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Sampelayo, T |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Pavón, J |e verfasserin |4 aut | |
| 700 | 1 | |a González Del Castillo, J |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Delgado, M C |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Sánchez, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Sellés, M |e verfasserin |4 aut | |
| 700 | 1 | |a Molero García, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Guillén, S |e verfasserin |4 aut | |
| 700 | 1 | |a García de Viedma, D |e verfasserin |4 aut | |
| 700 | 1 | |a Bouza, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 37(2024), 1 vom: 19. Feb., Seite 17-28 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2024 |g number:1 |g day:19 |g month:02 |g pages:17-28 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/123.2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2024 |e 1 |b 19 |c 02 |h 17-28 | ||